AstraZeneca PLC · AZN · FY2026 Q3 · Calendar Q4 2026
AstraZeneca pairs solid growth with pipeline investment and restructuring
AstraZeneca's current results support a constructive growth narrative: established franchises are growing, the pipeline is advancing, and new launches and restructuring are intended to support longer-term expansion. The thesis remains dependent on execution, pricing, regulatory outcomes and the ability to offset loss-of-exclusivity pressure.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about AZN FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The quarter added a $2 billion Reshaping for Sustainable Growth program, an equity investment and collaboration with Summit Therapeutics, and a first FDA breakthrough therapy designation for the B7-H4 ADC puxi-sam. Management also highlighted 12 positive Phase III readouts and four new product approvals.
Guidance delta
Management maintained its guidance sentiment while pointing to continued growth despite loss-of-exclusivity headwinds.
Key takeaways
- Revenue and core EPS growth remained solid despite anticipated loss-of-exclusivity headwinds.
- Pipeline momentum included 12 positive Phase III readouts and four new product approvals.
- The company announced a $2 billion restructuring program targeting up to $1.5 billion in pretax run-rate benefits.
Management priorities
- Advance oncology, rare-disease, respiratory and immunology franchises.
- Execute launches including Baxfendy, Etcamah and tozorakimab.
- Redeploy resources through Reshaping for Sustainable Growth while funding pipeline investment.
Follow AZN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationAstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
- ABBVFY2026 Q3 · October 30, 2026+2.4% EPS+1.4% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the AZN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-31T16:05:53.072503+00:00
- FN2 earnings calendar · 2026-10-31T01:23:13.065444+00:00
- Polygon adjusted daily market bars · 2026-10-31T16:10:42.024709+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T16:10:42.021587+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.